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A B S T R A C T
The aim of the study reported herein was to evaluate the suitability of the Surface Acoustic Wave (SAW)
technique as a possible diagnostic tool in benign prostatic hyperplasia (BPH). Moreover, for the ﬁrst time, the
BPH model was a totally physiological using naturally aged rats with spontaneous, age-related BPH instead of
the pharmacologically induced models usually used. Eighteen male Wistar rats were distributed according to
their age: 6 weeks (young), 12 weeks (adult) and 12 months (old) old. Prostate gland was removed and analyzed
by mini-arrays, Western blotting (WB) and SAW techniques. Mini-arrays indicated that there were signiﬁcant
diﬀerences in the expression of 29/34 inﬂammation-related cytokines. WB was carried out to conﬁrm the results
after selection of 4 cytokines from which one showed no changes, namely PDGF-AA, and the other three, which
signiﬁcantly increase in older animals, were CD86, β-NGF and VEGF. Notwithstanding, WB of old rats yielded
confusing results due to an anomalous migration of proteins, dismissing this technique as an useful tool in these
animals. Accurate results in old rats were uniquely obtained by using the SAW technique. Thus, SAW analysis
showed that there were not diﬀerences among groups in the amount of PDGF-AA. On the contrary, SAW analysis
showed that amounts of CD86, β-NGF and VEGF in old rats were 2.0, 1.9 and 5.7-fold higher than that from
young ones, respectively. These results indicate that SAW is a highly accurate technique for determining changes
in the cytokines expression in BPH.
1. Introduction
Age-related benign prostatic hyperplasia (BPH) is a very common
disease in elderly males in mammals [1,2]. One of the most common
features of BPH is the presence of an inﬂammatory process that can be
acute, chronic active or chronic inactive [3–6]. The prevalence of in-
ﬂammation in BPH is very high, ranging from 70% to 100% depending
on the study [7–9]. The clinical importance of this BPH-associated in-
ﬂammatory process is relevant, since some of the observed clinical signs
in BPH are a consequence of the enlargement of the prostate gland
induced by the inﬂammation process [10]. Thus, analyzing the BPH-
linked inﬂammation is important in order to improve both the diagnosis
and the prognosis of the process. Additionally, the adequate diagnosis
of BPH is relevant taking into consideration that this process is com-
monly lined with the ﬁrst steps in the instauration of prostate tumor
processes with much worst prognosis.
Inﬂammation is a complex process mediated by pro-inﬂammatory
cytokines, chemokines, prostanoids and growth factors [see 11 for a
review]. The etiology of prostatic inﬂammation is not completely elu-
cidated. At this time, the current data seems to indicate that the onset of
prostatic inﬂammation is launched under a multifactorial etiological
basis that involves factors such as infection [12,13], systemic in-
ﬂammation, components from both the environment and the diet,
oxidative stress, urine reﬂux and systemic steroids [14]. Despite this,
according to the literature, only ageing and androgenic imbalance, ei-
ther concomitantly or not, has been deﬁnitely related to BPH devel-
opment [15–17].
From a broad point of view, a close relationship between the de-
velopment of cancer, whether derived from a previous hyperplastic
process or not, and chronic inﬂammation has long been recognized
[18–21]. Thus, like BPH cells, tumor ones produce cytokines, chemo-
kines and growth factors, such as IL-1β, IL-3, IL-6, IL-11, IL-23, and
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TNF-α [22,23]. These mediators attract leukocytes, such as neutrophils,
macrophages, eosinophils, mast cells and lymphocytes [19]. The at-
tracted leukocytes in turn release several mediators, such as cytokines,
cytotoxic mediators and mediators of cell death [24,25].
Finally, the factors released from leukocytes then act on a broad
phenomenon linked not only to the inﬂammatory process, but also to
carcinogenesis, such as cell proliferation and migration, tissue re-
modeling, metabolism and genomic integrity. [26]. In this manner,
cytokines play an important role in carcinogenesis and subsequent de-
velopment of the tumor process as they are involved in apoptosis, an-
giogenesis and cell adhesion and transformation [27,28].
Prostatic diseases can be diagnosed and diﬀerentiated among them
using a wide variety of diagnostic tools. In this sense, the most common
diagnostic tool for detecting early prostate cancer in men is the de-
termination of serum prostate-speciﬁc antigen (PSA) levels. However,
PSA can be increased not only due to presence of prostatic cancer, but
also due to BPH or chronic prostatitis [36]. In addition, PSA levels can
also be altered due to the handling of samples, laboratory procedures
and standardizations [37], levels of serum androgens and ejaculations
[38,39]. Thus, results are not always completely reliable. Another im-
portant diagnostic tool for prostate alterations is biopsy. However,
prostatic biopsy also gives negative results up to two-thirds of patients
with prostatic alterations [36]. Therefore, new and more precise diag-
nostic tools are needed to reach accurate diagnosis in prostatic
pathologies. These diﬃculties in diagnosis are also accompanied with
troubles in ﬁnding an optimal laboratory model for the study of BPH
and/or prostatic tumors. Thus, these laboratory models have been ob-
tained basically from two sources. The ﬁrst source is male rats and mice
in which the BPH has been induced through the administration of in-
ducing substances like formalin, testosterone, sulpiride or even speciﬁc
microbial strains in order to induce prostate inﬂammation as a previous
step to the establishment of BHP [29–33]. The second source is speciﬁc
cell lines, such as LNCaP cell line [34] and PC3 cell line [35]. Both
sources, although reliable, do not strictly follow a physiological pattern
for the BPH onset, limiting thus their practical use in the precise
knowledge of BPH.
Taking all of this information into account, the aim of this manu-
script was focused on two aspects. The former was to explore the pos-
sibility of ﬁnding feasible techniques that could improve the diagnosis
of prostatic alterations, in order to avoid troubles linked to the cur-
rently utilized diagnostic tools, and the latter was to explore the pos-
sibility of utilizing ageing rats as a feasible model for the study of BPH.
In this sense, the search of a feasible technique that could be applicable
to the diagnostic of prostate alterations was centered on the Surface
Acoustic Wave (SAW) technique. In fact, the SAW technique has been
already applied to optimize diagnosis and even to develop potential
new therapeutically approaches in processes such Alzheimer's disease,
Parkinson's disease and epidermal growth factor-linked tumors
[40–44]. The main reason for the application of the SAW technique in
diagnosis/prognosis is centered in the fact that SAW is a very powerful
tool for label-free detection of a broad range of numerous analytes,
from small molecules, peptides, proteins and lipid membranes to whole
cells and cell cultures. SAW biosensor is a chip-based bioaﬃnity system
to study several aﬃnity interactions (antibody-protein, protein-protein,
ligand-protein, etc). The biosensor is based on the conversion of a high-
frequency signal into a surface acoustic wave due to the inverse pie-
zoelectric eﬀect. The velocity of the SAW is sensitive to changes in mass
loading, causing shifts in the amplitude and phase of the signal enabling
high sensitivity detection. Furthermore, interactions on the gold-coated
chip surface can be observed at near-physiologic conditions [45].
Regarding on the second aim of the study, the experimental model
used rats divided in three separate groups according to their age. The
levels of several inﬂammatory cytokines from prostate samples of male
Wistar rats of 6 weeks (young), 12 weeks (adult) and 12 months (old)
old were ﬁrstly analyzed by mini-array technique. It is important to
point out that this is the ﬁrst study that reports results from rats that
present spontaneous, age-related BPH, in contrast of previous reported
works that BPH was pharmacologically induced. Therefore, this age-
related model reﬂects in a more accurate manner the initial processes
leading to the onset of BPH. After an accurate analysis of the mini-
arrays results, the next step was to focus further analyses on 4 cytokines
that showed separate levels in age-related BPH, namely platelet-derived
growth factor AA (PDGF-AA), cluster of diﬀerentiation 86 (CD86),
nerve growth factor β (β-NGF) and vascular endothelial growth factor
(VEGF).
PDGF-AA has been described to play a relevant role in prostate
tumorigenesis as well as cancer progression. Nevertheless, regarding to
the literature, it has not been associated with BPH [46,47]. CD86,
which is also known as B-lymphocyte activation antigen B7-2, is a type I
membrane protein member of the immunoglobulin superfamily. CD86
is the ligand for two diﬀerent proteins on the T cell surface, CD28 (for
autoregulation and intercellular association) and CTLA-4 (for attenua-
tion of regulation and cellular disassociation) [48]. The co-stimulatory
signal through CD86 to its counter receptor CTLA-4 on T cells has been
shown to play an important role in the induction of T-cell-mediated
immunity against tumors [49]. NGF is a growth factor that is essential
for the development and maintenance of the nervous system, which is
also involved in angiogenesis, facilitating tumor genesis of breast, oral
and prostate cancers [50]. VEGF is a potent growth factor and angio-
genic cytokine that stimulates proliferation and survival of endothelial
cells, as well as promotes angiogenesis and vascular permeability [51].
VEGF is implicated in the induction of tumor metastasis and intraocular
neo-vascular syndromes [52,53].
Before the SAW analysis, mini-arrays results for these cytokines
were validated through a Western blot analysis, which conﬁrm the
speciﬁcity of the obtained results. Despite this, Western blot results of
samples from old rats show technical interferences that preclude the
utilization of this technique for an accurate detection of cytokines in
these animals, emphasizing the usefulness of the SAW technique for this
purpose. Results indicate that SAW can be a useful and practical tool for
an early diagnosis of BPH through the highly sensitive and speciﬁc
detection of changes in prostate protein expression.
2. Material and methods
2.1. Animals and sample collection
Eighteen Wistar male rats were included in the present study. The
animals were distributed into three diﬀerent groups according to their
age. The ﬁrst group was formed by 6 young males 6 week-old and
weighing from 178.66 g to 199.42 g. The second group was that of 6
adult males 12 week-old and weighing from 336.6 g to 416.8 g. Finally,
the third, old rats groups, included 6 rats 12 month-old, weighing from
612.3 to 745.0 g.
An intraperitoneal injection of a mixture (3:1; v: v) of ketamine,
100mg/Kg rat body mass (Imalgene®, Merial Laboratorios S.A.,
Barcelona, Spain), and xylacine, 10 mg/Kg rat body mass (Rompun®,
Bayer Hispania S.L., Barcelona, Spain), was used to euthanize animals.
Prostate glands were immediately surgically removed by medial la-
parotomy. Half of each prostate gland was ﬁxed with 10% paraf-
ormaldehyde, while the other half was snap frozen in liquid nitrogen
and kept frozen at − 80 °C until analyses were performed. The ex-
perimental protocol was approved by the Ethical Committee of the
University of Barcelona (DAAM-8153). All the experiments were per-
formed in accordance with the guidelines and regulations established
by the University of Barcelona.
2.2. Experimental design
Paraformaldehyde samples were used to perform the histological
study of the prostate glands with the aim of stablishing the degree of
benign prostatic hyperplasia. Additionally, frozen samples were used to
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analyze the expression of 34 cytokines on the prostate glands by mini-
arrays analysis. Once the expression of the diﬀerent cytokines was
analyzed and compared among the three groups of animals, four pro-
teins were selected for further analysis basing on the results obtained
through the miniarray analysis. The ﬁrst protein was PDGF-AA, which
did not show variations among experimental groups. The second and
third proteins, CD86 and β-NGF, showed signiﬁcant (P < 0.05) var-
iations in the old rats group when compared with the other experi-
mental ones. Finally, the fourth selected protein was VEGF, which
showed signiﬁcant (P < 0.05) variations among all experimental
groups. The proteins were subsequently analyzed through Western
blotting (WB) and Surface Acoustic Wave (SAW) techniques for quan-
tiﬁcation purposes.
2.3. Histology
After 24 h of 10% (w: v) paraformaldehyde ﬁxation, prostate sam-
ples were embedded in paraﬃn and 5 µm thick sections were obtained.
Paraﬃn sections were then stained with Harris’ haematoxylin-eosin and
analyzed under a light microscope.
2.4. Mini-arrays analysis
Thirty-four cytokines were evaluated with a commercial protein
mini-array system kit (RayBio® C-Series Rat Cytokine Antibody Array
C2, RayBiotech Inc., Norcross, GA, USA). The analyzed cytokines are
listed in Fig. 1. For this purpose, prostate gland samples were thawed in
1mL of the ice-cold extraction buﬀer included in the kit and im-
mediately homogenized by using an Ultra-Turmax® T25 basic homo-
genizer (IKA®-WERKE, Staufen, Germany). Samples were subsequently
centrifuged at 13000× g for 20min in a 4 °C chamber and supernatants
were kept. Total protein content of the supernatants was determined by
the Bradford method [54] using a commercial kit (Bio-Rad Protein
Assay Dye Reagent; Bio-Rad Laboratories Headquarters, Hercules, CA,
USA). Once total protein content was determined, samples were diluted
in the blocking buﬀer included in the mini-array kit to a ﬁnal protein
concentration of 500 μg/mL. Afterwards, mini-array analyses were
performed according to the manufacturer instructions. Brieﬂy, the
Antibody/Array membranes included in the kit were placed in a well-
tray provided by the manufacturer and incubated with 2mL of blocking
buﬀer for 30min. Next, the blocking buﬀer was decanted and 1mL of
sample was added to the wells and incubated for 2 h. Membranes were
subsequently washed thrice for 5min with a washing buﬀer (Washing
Buﬀer I) and thrice for 5min with another washing buﬀer (Washing
Buﬀer II). Both, Washing Buﬀer I and Washing Buﬀer II were included
in the kit. Then, the membranes were incubated with 1mL of the cor-
responding biotin-conjugated antibodies for 2 h. Membranes were wa-
shed again as previously described and immediately incubated with
2mL of HRP-conjugated streptavidin for 2 h. Subsequently, membranes
were subjected to a ﬁnal washing step with both, Washing Buﬀer I and
Washing Buﬀer II as previously described. All incubations described
herein were performed at room temperature. Finally, membranes were
incubated with the commercial detection buﬀer provided by the man-
ufacturer for 2min and exposed to X-ray ﬁlm. The resultant X-ray ﬁlms
from cytokines were scanned and the intensity of the expression ana-
lyzed using an image analyzer (Multi Gauge 2.0, Fujiﬁlm Europe,
Düsseldorf, Germany). This software provided a numerical expression
of intensity in arbitrary units for every single analyzed spot. An equa-
tion of expression was calculated from the mean numeric expression of
the positive and the blank spots (Fig. 2) in order to quantify the in-
tensity of every cytokine spot. In order to clarify the possible statistical
diﬀerences among the evaluated groups, the percentage obtained for
adult rats was transformed into 100%, while young and old rats values
were transformed into their corresponding percentage by multiplying
by the factor used to transform the adult value into 100%.
2.5. Western blotting analysis
Western blotting analysis was performed according to Sirois and
Dore [55]. Brieﬂy, after determining protein concentration by the
Bradford technique, proteins were separated by SDS-PAGE electro-
phoresis in 10% (w: v) acrylamide gels and transferred to nitrocellulose
membranes. The eﬃcacy of transference was evaluated by 0.1% Pon-
ceau S dye (w:v). Membranes were then incubated with 5% (w: v) BSA
diluted in Tris-Buﬀered Saline (TBS) solution (25mM Tris-HCl, pH 7.4,
0.14mM NaCl) during 1 h at room temperature to block non-speciﬁc
binding. Afterwards, membranes were probed against PDGF-AA (R&D
Systems; Abingdon, UK), B7-2/CD86, β-NGF and VEGF (Novus Biolo-
gicals, Littleton CO, USA) antibodies at a 1:1000 concentration. Anti-
body binding was visualized by chemiluminescence (Western blotting
luminol reagent, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA)
according to the manufacturer's instructions and exposed to X-ray ﬁlm.
Once cytokines expression was evaluated, membranes were exposed
to a stripping buﬀer (0.2 M glycine, 0.05mM Tween 20, pH 2.2) to
remove primary antibodies for PDGF-AA, CD86, β-NGF and VEGF and
their corresponding secondary antibody. Then, the membranes were
blocked again and exposed to α-tubulin antibody (ABR Aﬃnity
BioReagents, CU, USA), which was used as an internal standard to
verify that the same amount of protein was loaded for every sample.
Finally, X-ray ﬁlms from every cytokine and their corresponding α-tu-
bulin were scanned and the intensity of the expression analyzed using
an image analyzer (Multi Gauge 2.0, Fujiﬁlm Europe, Düsseldorf,
Germany).
2.6. Surface Acoustic Wave technique
Bioaﬃnity analyses of prostate homogenates were performed with a
Sam5 Blue SAW biosensor (Nanotemper, Munich, Germany). This de-
vice consists of a biosensor unit, an auto-sampler and a microchip
module with a gold layer sensing surface on a quartz chip. The chip
surface was coated with dextran and functionalized with a ﬂat 16-
mercaptohexadecanoic acid self-assembled monolayer (COOH-SAM), as
previously described [56].
Antibody against studied cytokines was immobilized on the SAM by
carboxyl-group activation with 200mM (1-ethyl-3-(3-dimethylamino-
propyl)-carbodiimide (EDC) and 50mM N-hydroxysuccinimide (NHS)
[57]. A solution of 500 nM of Anti-cytokine antibody (300 µL) was
immobilized on the SAM, followed by capping of unreacted carboxyl
groups with 1M ethanolamine, pH 8.5. Dilutions of homogenate sam-
ples were injected and aﬃnity binding performed at a ﬂow rate of
15 µL/min. Furthermore, to avoid the aggregation of proteins as well as
their nonspeciﬁc interactions with the biosensor chip devices, 0.005%
(v:v) Tween20 and 3mM EDTA was required in the running PBS buﬀer
for bioaﬃnity binding analysis [58,59]. Thus, all aﬃnity binding
Fig. 1. List of analyzed cytokines by mini-arrays technique. Each cytokine was
analyzed by duplicate in each in two separate spots. Thus, in each array the
value intensity of each cytokine was determined as the mean intensity of both
spots.
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experiment were performed in PBS buﬀer (pH 7.5) with 0.005% (v: v)
Tween20 and 3mM EDTA at room temperature. At the end of each
measurement cycle (which is an injection of an homogenate sample for
measurement of cytokine aﬃnity interaction with its respectively im-
mobilized antibody), the sensor chip surface was washed by a 30–40 µL
injection of 0.5% (w: v) sodium dodecyl sulfate (SDS) in the running
buﬀer at 15 µL/min, to remove the tightly bound proteins from the
surface, and the baseline of the sensorgram returned to the same level
to that before the injection of the homogenate sample. Binding curves
were analyzed using the Origin Pro v8.5.1 SR2 software (OriginLab,
Northampton, USA) and the integrated FitMaster V 4.2 (Nanotemper,
Munich, Germany).
2.7. Statistical analyses
Statistical analyses were performed using the SPSS 21.0 software
(SPSS Inc., Chicago, IL, USA). Data were compared through one-way
analysis of variance (ANOVA) to stablish the diﬀerences among the
three groups included in the study. The minimal level of signiﬁcance
was set at P < 0.05.
3. Results
3.1. Histology
All of the analyzed rats pertaining to the young animal group (6
weeks old) showed a normal histological architecture of the prostatic
tissue with no sign of prostatic hyperplasia (Figs. 3A1, 3A2). Otherwise,
all of the adult rats group (12 weeks old) showed slight benign prostatic
hyperplasia characterized by the presence of irregular glands, poorly
delimited prostatic lobes and slight inﬂammatory inﬁltration
(Figs. 3B1, 3B2). Finally, all animals included in the old rats group (12
months old) showed moderate to severe benign prostatic hyperplasia
characterized by the presence of atrophied prostatic glands, pro-
liferative epithelium, hyperchromatic cells and severe inﬂammatory
inﬁltrate (Figs. 3C1, 3C2).
3.2. Mini-arrays
The mini-array allowed analyzing the expression of a total of 34
inﬂammation-related cytokines. Of the 34 cytokines analyzed, 29
showed statistically signiﬁcant (P < 0.05) diﬀerences. Only Fas
Ligand, IL-13, MMP-8, PDGF-AA and RAGE showed no statistical dif-
ferences among the evaluated groups (Fig. 1). Furthermore, 25 out of
29 cytokines that showed any signiﬁcant diﬀerence also showed a
signiﬁcant (P < 0.05) increase in the old rats group when compared
with the other two groups. Likewise, these 25 cytokines did not show
any signiﬁcant diﬀerence when comparing young and adult rats groups
(Table 1). Finally, the other 4 cytokines out from the 29 ones that
showed signiﬁcant diﬀerences yielded signiﬁcant (P < 0.05) diﬀer-
ences among the three evaluated groups (young, adult and old rats).
These 4 cytokines were CINC-3, MCP-1, TIMP-1 and VEGF (Table 1).
Furthermore, the highest amount observed for this 4 cytokines were
obtained in the old rats group, whereas the young animals group
showed signiﬁcantly (P < 0.05) lower values of all 4 proteins when
compared with both the adult rats group and the old animals one
(Table 1).
3.3. Western blotting
No signiﬁcant diﬀerences were observed in PDGF-AA expression
when comparing young and adult rats. In addition, the increase of the
VEGF intensity band in adult rats when compared with the young ones
(Fig. 4) was much more evident than that observed in case of both CD86
and β-NGF (data not shown). Regarding to old rats, Western blotting
yielded no clear bands, but a greatly diﬀuse spot on the X-ray ﬁlm that
precluded any possible analysis of bands in these animals.
3.4. Surface Acoustic Wave technique
On one hand, in the chip functionalized with Anti-rPDGF-AA, any
interaction was observed with the diluted 1/1000 samples showing that
the concentration of PDGF-AA protein was too low. However, when
samples were diluted 1/100 in PBS and injected to the biosensor, as-
sociation and dissociation curves were clearly detected indicating that
the concentration of the targeted protein was high enough. No sig-
niﬁcant diﬀerences in bioaﬃnity were observed among diluted 1/100
young, adult and old rat prostate samples (Fig. 5A)
On the other hand, statistically signiﬁcant diﬀerences (P < 0.05) in
CD86, β-NGF and VEGF concentration in young, adult and old rat
prostate homogenates were detected (Fig. 5B). To relatively quantify
the amounts of cytokines present in the three groups of animals, the
maximum value of phase for each sample was taken and statistical
treatment was performed. Following this analysis, the concentration of
CD86 and β-NGF in prostate homogenates of adult rats were 1.3 and
1.4-fold upper than that in young rats, whereas their concentrations in
old rats were 2.0 and 1.9-fold greater than that in adult rats, respec-
tively (Figs. 5C and 5D). Finally, the VEGF concentration in adult rat
prostate samples was 2.5-fold higher than that in young rat prostate
samples. However, the VEGF concentration in old rat prostate homo-
genates was more than 5.7-fold higher than that observed in young rat
homogenates (Fig. 5E).
4. Discussion
In the present study, the suitability of the SAW technique as a di-
agnostic tool for BPH taking as a basis the BPH-linked changes in
prostate expression of speciﬁc cytokines is brought to light for the ﬁrst
time. In fact, the previous mini-arrays analysis already showed the BPH-
linked cytokines expression alteration of prostate parenchyma, since of
the 34 analyzed cytokines, 29 showed some statistically signiﬁcant
diﬀerence among the diﬀerent groups, with old rats showed
Fig. 2. Equation of cytokines expression evaluated by mini-arrays. The equation was calculated from the mean numeric expression of the positive and the blank spots
in order to later quantify the intensity of every cytokine spot.
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signiﬁcantly higher values in all cases (Table 1). Taking into account
the close relationship between inﬂammation and the increase of cyto-
kines expression, our results would logically indicate that inﬂammatory
changes linked to age in the prostatic parenchyma are related with the
presence of cytokines in the prostatic parenchyma. These results are in
agreement with previous studies which have observed that the BPH-
associated prostatic inﬂammation is characterized by an elevated pre-
sence of T cells as well as several cytokines from the interleukin (IL)
family [60–72], IFN-γ [71,73] and TGF-β [67,71,74–78]. However, it is
noteworthy that all of these previous studies focused on in vivo induced
BPH in rats have been performed in pharmacologically induced-BPH
[see 79–81 for some examples]. This will surely induce important dif-
ferences in the speciﬁc expression of cytokines when comparing with
the results showed in this manuscript, since the inﬂammatory me-
chanisms launched here are strictly related with aging. This implies
that, in case of this manuscript, the induction of a prostate in-
ﬂammatory response was not acute as was that induced by drugs as in
previous studies, [79–81]. In this way, taking into account the great
diﬀerences in both the timing and the aggressiveness of the in-
ﬂammatory induction between spontaneous aging BPH model and
pharmacologically-induced BPH one, it is reasonable to detect diﬀer-
ences in the speciﬁc expression of cytokines in both models. Moreover,
the slow, chronic inﬂammatory response associated with aging is a
Fig. 3. Prostate gland histology. A1) Prostate gland from a young rat, 200 µm magniﬁcation. A2) Prostate gland from a young rat. 100 µm magniﬁcation. Note the
absence of inﬂammatory response and tissue hyperplasia. B1) Prostate gland from an adult rat, 200 µm magniﬁcation. Note the presence of irregular glands
indicating the presence of BPH. B2) Prostate gland from an adult rat. 50 µm magniﬁcation. Note the presence of poorly delimited prostatic lobes and inﬂammatory
inﬁltration, indicative of light benign prostatic hyperplasia. C1) Prostate gland from an old rat. 200 µm magniﬁcation. Note the presence of atrophied prostatic glands
with proliferative epithelium and hyperchromatic cells. C2) Prostate gland from an old rat. 50 µm magniﬁcation. In addition to the glandular atrophy and the
proliferative epithelium, inﬂammatory inﬁltrate can be also observed, indicating a moderate to severe benign prostatic hyperplasia.
Table 1
Cytokines quantiﬁcation, expressed in percentage, analyzed by mini-arrays
technique.
Cytokine Young rats (n= 6) Adult rats (n= 6) Old rats (n= 6)
Fas Ligand 111.59 ± 28.46ª 100.00 ± 7.44ª 68.47 ± 21.51ª
IL− 13 102.33 ± 34.75ª 100.00 ± 19.19ª 103.87 ± 43.90ª
MMP− 8 ND 100.00 ± 103.40ª 67.56 ± 24.93ª
PDGF-AA 73.38 ± 7.35ª 100.00 ± 27.96ª 115.67 ± 12.80ª
RAGE 77.62 ± 13.07ª 100.00 ± 42.46ª 125.84 ± 13.45ª
Activin A 128.4 ± 33.7ª 100.0 ± 46.0ª 3386.3 ± 255.4b
Agrin 89.5 ± 6.7ª 100.0 ± 14.5ª 129.5 ± 9.9b
CD86 97.0 ± 20.7ª 100.0 ± 7.6ª 318.6 ± 50.4b
β-NGF 82.8 ± 20.4ª 100.0 ± 7.1ª 674.2 ± 45.1b
CINC− 1 95.0 ± 13.0ª 100.0 ± 5.3ª 165.8 ± 22.7b
CINC− 2α 98.7 ± 11.6ª 100.0 ± 9.7ª 231.7 ± 29.4b
CNTF N. D. 100.0 ± 100.1a 975.5 ± 121.7b
Fractalkine N. D. 100.0 ± 10.2a 1098.5 ± 142.6b
GM-CSF 105.5 ± 184.5a 100.0 ± 71.3a 9912.0 ± 1947.5b
ICAM− 1 230.0 ± 105.4a 100.0 ± 50.7a 1544.9 ± 238.7b
INF-γ 172.8 ± 53.0a 100.0 ± 44.3a 1190.2 ± 136.8b
IL-α 110.2 ± 17.0ª 100.0 ± 9.3a 194.5 ± 10.8b
IL-β N. D. 100.0 ± 79.1a 5094.0 ± 802.4b
IL− 1 R6 N. D. 100.0 ± 73.1a 3270.5 ± 312.1b
IL− 2 41.7 ± 36.4a 100.0 ± 74.0a 1285.0 ± 76.0b
IL.4 N. D. 100.0 ± 69.6a 1086.9 ± 120.0b
IL− 6 N. D. 100.0 ± 81.0a 4706.9 ± 610.6b
IL− 10 N. D. 100.0 ± 102.8a 3244.2 ± 641.9b
Leptin 58.3 ± 35.1a 100.0 ± 40.8a 691.6 ± 94.3b
LIX 70.7 ± 11.0a 100.0 ± 33.8a 554.9 ± 50.0b
L-selectin N. D. 100.0 ± 45.4a 2273.1 ± 244.6b
MIP− 3α 37.7 ± 15.1ª 100.0 ± 61.7a 831.7 ± 122.2b
Prolactin R 107.6 ± 33.6ª 100.0 ± 25.9a 297.1 ± 99.3b
Thymus
chemokine
100.5 ± 5.5ª 100.0 ± 23.7a 172.0 ± 13.8b
TNF-α N. D. 100.0 ± 100.0a 8711.1 ± 1468.4b
CINC− 3 75.0 ± 9.2a 100.0 ± 5.5b 160.1 ± 35.0c
MCP− 1 24.5 ± 15.8a 100.0 ± 48.3b 1571.5 ± 154.9b
TIMP− 1 29.3 ± 4.2a 100.0 ± 31.1b 203.2 ± 25.5c
VEGF 68.7 ± 8.8a 100.0 ± 16.5b 198.9 ± 18.2c
Results are expressed as mean± s.e.m. Minimal level of signiﬁcance was set at
P < 0.005. Diﬀerences among the groups are expressed with diﬀerent super-
scripts letters. N.D.: Not detected.
Fig. 4. Western blotting for PDGF-AA, CD86, β-NGF and VEGF. No signiﬁcant
diﬀerence between young and adult rats in PDGF-AA expression were observed.
In the case of CD86 and β-NGF, their expression in between young and adult
rats had slightly diﬀerences, while adult rats showed a signiﬁcant higher ex-
pression than young rats for VEGF.
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much more physiological mechanism to induce BPH, and probably
closer to the spontaneous process. Thus, we would recommend an
aging-based rat model to study the mechanism/s involved in the
launching of BPH, since this model could more precisely emulate the
mechanisms involved in the spontaneous process, increasing the accu-
racy in the interpretation of results. In this sense, the information
yielded by our results indicate that the older is the animal, the more
severe are the changes in the prostatic tissue and also the expression of
pro-inﬂammatory cytokines would have a more prominent prospective
value in order to understand the progressivity of the inﬂammatory
process linked to BPH than results obtained through other, non-spon-
taneous but artiﬁcially induced, in vivo experimental models. Taking
this into account, our results showed that only Fas-Ligand, IL-13, MMP-
8, PDGF-AA and RAGE showed no statistical diﬀerence in their ex-
pression among the three evaluated groups. On the other hand, only
CINC-3, MCP-1, MIP-3α, TIMP-1 and VEGF showed signiﬁcant
Fig. 5. Quantiﬁcations of cytokine's
amounts in rat prostate homogenate
samples by SAW technique. Average of
SAW sensograms of PDGF-AA (A),
CD86 (B), β-NGF (C) and VEGF (D)
(Left) and their concentrations in
young, adult and old rat prostates
(Right). The PDGF-AA concentration in
the three evaluated groups of rats is not
signiﬁcantly diﬀerent, while the CD86
and β-NGF concentrations among these
groups are statistical diﬀerent. Besides,
the VEGF concentration in young, adult
and old rat prostates is clearly and
signiﬁcantly diﬀerent. A relatively
quantiﬁcation of cytokine concentra-
tion could be done after a statistical
treatment of data. The phase's values at
20 s before the end of an injection
period are plotted as a bar graphic.
Data are expressed as mean±
standard deviation values.
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diﬀerences among young, adult and old male rats. However, CD86 and
β-NGF did not present signiﬁcant diﬀerences between young and adult
rats, but an important statistical diﬀerence between adult and old rats.
As detailed above, according to the results obtained with the mini-
arrays, four cytokines were selected for further analyses. On the one
hand, PDGF-AA was selected as a negative control because no sig-
niﬁcant diﬀerence among the three groups was observed. Due to the
fact that CD86, β-NGF and VEGF showed statistically signiﬁcant dif-
ferences among at least two evaluated groups of rats and its previously
described speciﬁc relationship with prostatic pathologies, they were
selected as positive controls. Both PDFG-AA and VEGF are involved in
the process of vasculogenesis and angiogenesis [82,83], which are
closely related with both inﬂammation [84,85] and prostate alterations
like BPH and carcinoma [86–91], although the exact role of both cy-
tokines is not well known. This is highlighted in the case of PDGF-AA,
which, according to the literature, has not been associated with BPH.
However, since none of the old individuals included in the study was
diagnosed with prostatic carcinoma we cannot aﬃrm or exclude a
possible role of PDGF-AA in the tumorigenesis process of rat prostate.
On the contrary, the strong neovascularizating action of VEGF has been
widely related with prostatic pathologies [92–94], emphasizing thus
the importance of our results. Additionally, in the case of CD86 and β-
NGF both cytokines were reported to participate in carcinogenesis
[49,50]. These results are in concordance with the results obtained in
the mini-array analysis, where a signiﬁcant increase of CD86, β-NGF
and, specially, VEGF expression has been detected in old individuals.
The results obtained in this manuscript clearly indicate that Western
blotting was not appropriate for the analyses of prostatic tissue even to
conﬁrm the results observed through the mini-array technique. This is
evident in samples from old rats, which showed no clear band, re-
gardless the antibody analyzed, but a dispersed and diﬀuse spot that
made the quantitative analyses impossible. A possible explanation
might be the changes in the extracellular matrix (ECM) of the prostate
gland. The ECM of the prostate gland is composed by a network of
glycoproteins, glycosaminoglycans and proteoglycans [92]. It is known
that changes in the ECM in some tissues, such as the prostate gland,
increase the risk of disease with age [93,94]. Several glycosaminogly-
cans [95,96], as well as glycoproteins [97], are increased in prostatic
pathologies, including age-linked hyperplasia. Thus, the high con-
centration of these substances in the prostate gland might turn Western
blotting into a non-suitable technique for analyzing prostatic samples
from old rats. Obviously, a deeper analysis to conﬁrm that the altera-
tion in the ECM components alters the eﬃcacy of the Western blotting
technique would be needed.
In contrast with Western blotting, the SAW technique yield suitable,
reproducible and sensitive results when analyzing the expression of the
selected cytokines. This great improvement is closely related by the
mechanisms in which is based this technique. The most important point
was the utilization of a Sam5 Blue Biosensor (Nanotemper, Munich,
Germany). This sensor is a chip-based bioaﬃnity system for marker-free
detection of a wide range of aﬃnity biomolecular interactions such as
antibody-protein, protein-protein or ligand-protein interactions. The
very high sensitivity of this sensor implies that the antigen-antibody
interactions on the gold-coated chip surface can be observed at near-
physiologic conditions [47]. Furthermore, the molecular structure of
the sensor implies that when prostate homogenate samples from young,
adult and old male rats were analyzed by SAW technique, the alteration
of ECM components present in old rat samples that ruined the Western
blotting results did not aﬀect the detection of cytokines. Therefore, the
SAW technique has demonstrated its high eﬃcacy and sensitivity to
analyze the concentration of cytokines in prostatic tissue, especially in
problematic samples. Therefore, from a clinical point of view, SAW
technique should be taken into consideration as a useful diagnostic tool
in prostatic pathologies in a future. It is true that the SAW technique
does not avoid the invasiveness, since a biopsy sample from the prostate
gland is required. However, if prostatic biopsy reaches up to two thirds
of wrong diagnosis [38], SAW technique could be a very promising
future diagnostic tool. Obviously, more research is needed to stablish its
actual usefulness. In the present study, 6 samples from each age group
were analyzed and results were highly homogenous. However, more
individuals should be included in further studies in order to reach a
reliable diagnostic tool.
5. Conclusions
In conclusion, our results indicate that the utilization of aged rats is
a highly feasible and physiological model to study age-related prostate
alterations which will render more accurate information regarding the
all of clinical and mechanistic aspects linked with the onset of prostate
alterations. In fact, the physiological origin of the model would be of it
a much accurate study model than other more commonly utilized at
these moments, such as the study on speciﬁc cell lines or the “in vivo”
analysis in pharmacologically-induced prostate alterations. Moreover,
our results also indicate that the introduction of the SAW technique
would imply a signiﬁcant improvement in the sensitivity and precision
of the diagnosis of prostate processes, aiding thus to improve the ap-
propriate management of these processes.
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